Last reviewed · How we verify
Anthracycline/dexamethasone-based induction chemotherapy
Anthracycline chemotherapy intercalates into DNA to prevent replication, while dexamethasone suppresses immune-mediated inflammation and enhances chemotherapy efficacy.
Anthracycline chemotherapy intercalates into DNA to prevent replication, while dexamethasone suppresses immune-mediated inflammation and enhances chemotherapy efficacy. Used for Acute leukemia induction therapy, Lymphoma induction therapy.
At a glance
| Generic name | Anthracycline/dexamethasone-based induction chemotherapy |
|---|---|
| Also known as | ID, VAD, CAD |
| Sponsor | WiSP Wissenschaftlicher Service Pharma GmbH |
| Drug class | Combination chemotherapy regimen |
| Target | DNA (anthracycline); glucocorticoid receptor (dexamethasone) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Anthracyclines (such as daunorubicin or doxorubicin) are topoisomerase II inhibitors that intercalate into DNA, causing strand breaks and preventing cancer cell proliferation. Dexamethasone, a corticosteroid, reduces inflammation and may enhance chemotherapy tolerability by suppressing immune activation. This combination is used as induction therapy in hematologic malignancies to achieve rapid cytoreduction.
Approved indications
- Acute leukemia induction therapy
- Lymphoma induction therapy
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Cardiotoxicity
- Mucositis
- Nausea and vomiting
- Infection
- Hyperglycemia (dexamethasone-related)
Key clinical trials
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents (PHASE3)
- Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia (PHASE1)
- Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment (PHASE3)
- Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia (PHASE1)
- Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma (PHASE2)
- Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia (PHASE1)
- Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |